In this issue of Cell, Ji and colleagues describe the development of SBI-810, a β-arrestin-biased modulator of neurotensin receptor 1 (NTSR1). This compound provides potent analgesia in rodent models of acute and chronic pain without side effects. This study highlights the therapeutic potential of targeting arrestin-biased GPCR signaling for non-opioid pain management.